Recruiting
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
NCT07418034· Phase 2· University of Maryland, Baltimore· Source
Contact: Kelly Kitzmiller
Recruiting
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NCT07452458· Phase 3· NRG Oncology· Source
Contact: Mark V. Mishra (principal investigator)
Recruiting
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Zaker H. Rana (principal investigator)
Recruiting
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
NCT07415681· Phase 2· University of Maryland, Baltimore· Source
Contact: Caitlin Eggleston
Recruiting
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
NCT06800339· Phase 1· University of Maryland, Baltimore· Source
Contact: Caitlin Eggleston, MPH
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
NCT06546969· Phase 1· University of Maryland, Baltimore· Source
Contact: Caitlin Eggleston
Recruiting
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
NCT06088381· Phase 2· University of Maryland, Baltimore· Source
Contact: Kelly Kitzmiller
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Melissa A. Vyfhuis (principal investigator)
Recruiting
TERPS Trial for de Novo Oligometastic Prostate Cancer
NCT05223803· Phase 2· University of Maryland, Baltimore· Source
Contact: Nicole Helie
Active, not recruiting
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
NCT04609280· Phase 2· University of Maryland, Baltimore· Source
Recruiting
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NCT04699773· University of Maryland, Baltimore· Source
Contact: Mark Mishra, MD
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755· Phase 1· University of Maryland, Baltimore· Source
Active, not recruiting
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NCT03801876· Phase 3· NRG Oncology· Source
Active, not recruiting
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03609216· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NCT03186898· Phase 3· NRG Oncology· Source
Active, not recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· Phase 3· NRG Oncology· Source
Active, not recruiting
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086· Phase 2· NRG Oncology· Source
Active, not recruiting
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
NCT01993810· Phase 3· Radiation Therapy Oncology Group· Source
Active, not recruiting
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
NCT01770418· Phase 1/2· Proton Collaborative Group· Source
Active, not recruiting
Proton Radiation for Stage II/III Breast Cancer
NCT01758445· Phase 2· Proton Collaborative Group· Source
Recruiting
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721· Massachusetts General Hospital· Source
Contact: Young Kwok, MD
Active, not recruiting
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
NCT01230866· Phase 3· Proton Collaborative Group· Source
Recruiting
Registry Study for Radiation Therapy Outcomes
NCT01255748· Proton Collaborative Group· Source
Contact: Caitlin Eggleston